When to Order Imaging for Monitoring Response to Neoadjuvant Systemic Therapy for Breast Cancer: ACR Appropriateness Decoded

When to Order Imaging for Monitoring Response to Neoadjuvant Systemic Therapy for Breast Cancer: ACR Appropriateness Decoded

A patient with newly diagnosed, locally advanced breast cancer is scheduled to begin neoadjuvant systemic therapy (NST). The oncologist needs a baseline assessment of the tumor size and nodal status to plan treatment and monitor response. You need to determine the most appropriate initial imaging to establish this baseline and guide subsequent care. Choosing between magnetic resonance imaging (MRI), ultrasound, and mammography requires understanding the strengths of each modality in this specific context. This guide decodes the American College of Radiology (ACR) Appropriateness Criteria to help you select the right study for the right clinical question when monitoring response to neoadjuvant therapy for breast cancer.

What Does ACR Monitoring Response to Neoadjuvant Systemic Therapy for Breast Cancer Cover?

This ACR guideline focuses on the use of imaging to evaluate breast cancer before, during, and after the administration of neoadjuvant systemic therapy. The criteria address several distinct clinical scenarios, including the initial assessment of the primary breast tumor, the evaluation of axillary lymph nodes, and staging for suspected metastatic disease. The recommendations apply to adult patients of any gender identity with known breast cancer who are candidates for or are undergoing neoadjuvant treatment.

These criteria are specifically for monitoring treatment response and do not cover initial cancer diagnosis, screening, or surveillance after completion of all therapy (surgery, radiation, and systemic treatment). The guidelines provide a framework for selecting the most effective imaging modalities to measure tumor response, which is critical for surgical planning and prognostic assessment. The scenarios differentiate between evaluating the primary breast lesion, assessing clinically node-negative versus node-positive axillae, and workup for distant disease.

What Imaging Should I Order for Monitoring Response to Neoadjuvant Systemic Therapy for Breast Cancer? Recommendations by Clinical Scenario

Selecting the optimal imaging study depends on the specific clinical question, such as initial staging, axillary assessment, or post-treatment evaluation.

For the initial determination of tumor size and extent within the breast prior to neoadjuvant chemotherapy, several modalities are rated as Usually appropriate. These include breast ultrasound, diagnostic digital breast tomosynthesis (DBT), diagnostic mammography, and MRI breast without and with IV contrast. MRI is particularly valuable for assessing the full extent of disease, especially in cases of lobular carcinoma or dense breast tissue. Similarly, for imaging of the breast after initiation or completion of neoadjuvant chemotherapy, the same set of studies—US, DBT, mammography, and contrast-enhanced MRI—are also considered Usually appropriate to assess for residual disease and guide surgical planning.

Axillary evaluation is a critical component of staging. For a patient who is clinically node-negative prior to neoadjuvant chemotherapy, an axillary ultrasound is Usually appropriate to confirm the nodal status. If imaging is suspicious, biopsy would then be performed. However, for a patient who is clinically node-positive prior to neoadjuvant chemotherapy, axillary ultrasound is also Usually appropriate. In this scenario, contrast-enhanced breast MRI and FDG-PET/CT are rated as May be appropriate for a more comprehensive assessment of the nodal basin and for systemic staging.

If axillary imaging is suspicious for metastatic disease on a prior study, the next step is tissue sampling. Both US-guided core biopsy and US-guided fine needle aspiration (FNA) of an axillary node are rated as Usually appropriate to confirm metastatic involvement. After completion of neoadjuvant therapy in a patient with known axillary lymph node-positive disease, a follow-up axillary ultrasound is Usually appropriate to assess response and guide further surgical management, such as targeted axillary dissection.

When there is a clinical suspicion of metastatic disease, either for initial staging or to assess treatment response, more extensive imaging is warranted. In this context, a whole-body bone scan, CT of the chest, abdomen, and pelvis with IV contrast, and FDG-PET/CT from skull base to mid-thigh are all considered Usually appropriate to evaluate for distant metastases.

ACR Imaging Recommendations Table

Adult vs. Pediatric Monitoring Response to Neoadjuvant Systemic Therapy for Breast Cancer Imaging: Radiation Dose Tradeoffs

While breast cancer is exceedingly rare in the pediatric population, the ACR guidelines provide pediatric radiation relative dose levels (RRLs) for applicable studies. The core principles of imaging remain the same, but the emphasis on radiation safety is heightened. For non-ionizing modalities like ultrasound and MRI, the dose is zero for all patients, making them highly preferred when clinically appropriate.

For studies involving ionizing radiation, such as FDG-PET/CT and bone scans, the pediatric RRLs are often in a similar or slightly lower tier than their adult counterparts (e.g., 3-10 mSv for pediatric PET/CT vs. 10-30 mSv for adults). This reflects dose adjustments made for smaller body habitus and reinforces the As Low As Reasonably Achievable (ALARA) principle. Clinicians must weigh the diagnostic necessity of any radiation-based study against the long-term risks of cumulative radiation exposure in younger patients. In any scenario where multiple modalities are appropriate, the option with the lowest radiation dose should be strongly considered for pediatric patients.

Imaging Protocol Details for Monitoring Response to Neoadjuvant Systemic Therapy for Breast Cancer

Once you’ve decided on the right study, the protocol matters. A well-executed protocol is essential for accurate assessment of treatment response. Our protocol guides cover technique, contrast administration, and interpretation principles for the key studies recommended in these guidelines.

• MRI Breast With and Without Contrast
• Nuclear Medicine Bone Scan (Whole Body)
• Breast Biopsy (Ultrasound-Guided)

Tools to Help You Order the Right Study

Navigating imaging guidelines can be complex. GigHz provides a suite of tools designed to support clinical decision-making and streamline the ordering process for physicians and trainees.

For scenarios not covered here, the ACR Appropriateness Criteria Lookup tool provides direct access to the complete, up-to-date ACR guidelines for hundreds of clinical topics, ensuring you can find evidence-based recommendations for virtually any presentation.

To ensure studies are performed correctly, the Imaging Protocol Library offers detailed, step-by-step protocols for a wide range of imaging procedures, including the specific MRI and nuclear medicine studies relevant to breast cancer staging and monitoring.

When discussing the risks and benefits of imaging with patients, especially concerning studies with ionizing radiation, the Radiation Dose Calculator is an invaluable resource. It helps estimate cumulative radiation exposure and provides clear, patient-friendly explanations of dose levels.

Why is breast MRI usually appropriate both before and after neoadjuvant therapy?

Breast MRI with IV contrast is highly sensitive for detecting and measuring invasive breast cancer. Before therapy, it provides the most accurate assessment of tumor extent, which is crucial for treatment planning. After therapy, it is the best modality for evaluating the amount of residual enhancing tumor, which is a key predictor of pathologic complete response (pCR) and helps guide the extent of surgery.

When is a PET/CT scan indicated for breast cancer in the neoadjuvant setting?

An FDG-PET/CT scan is rated as Usually appropriate when there is a clinical suspicion of metastatic disease, particularly for patients with locally advanced disease (e.g., large tumors or extensive nodal involvement). It provides a whole-body survey to detect distant metastases in bones, lymph nodes, and visceral organs, which can significantly alter the treatment plan and prognosis. It is also rated as May be appropriate for initial axillary evaluation in clinically node-positive patients.

Why is axillary ultrasound the first-line study for evaluating lymph nodes?

Axillary ultrasound is considered Usually appropriate for the initial evaluation of lymph nodes because it is non-invasive, does not use ionizing radiation, is widely available, and is highly effective at identifying suspicious nodes. Most importantly, it provides real-time guidance for fine-needle aspiration (FNA) or core biopsy to confirm or rule out metastatic involvement, which is a critical step in staging.

What is the role of mammography after neoadjuvant chemotherapy?

Mammography (including digital breast tomosynthesis) remains Usually appropriate after neoadjuvant chemotherapy. While MRI is superior for assessing residual enhancing soft tissue masses, mammography is essential for evaluating tumor-associated calcifications. These calcifications may not resolve with chemotherapy even if the invasive tumor does, and their extent can influence surgical planning. A clip placed in the tumor bed before therapy also helps identify the original tumor location on post-treatment mammograms.

Why is an MRI of the breast without IV contrast “Usually Not Appropriate”?

The key value of MRI in assessing breast cancer response to therapy lies in evaluating tumor vascularity and enhancement patterns. Malignant tissue typically shows avid enhancement after the injection of gadolinium-based contrast. An MRI performed without contrast cannot provide this functional information. It cannot reliably distinguish residual viable tumor from post-treatment scarring or fibrosis, making it inadequate for monitoring therapeutic response.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 12, 2026